OKYO / OKYO Pharma appoints leading US ophthalmology expert to its scientific board

OKYO Pharma Ltd (NASDAQ:OKYO), the clinical-stage drug developer noted, told investors it has filed an Investigational New Drug (IND) application wit more_horizontal

OKYO Pharma Ltd (NASDAQ:OKYO), the clinical-stage drug developer, has reported encouraging safety data for its ongoing phase II clinical trial of OK-1 more_horizontal

OKYO Pharma Ltd (NASDAQ:OKYO) has announced a public offering of its shares with the net proceeds to fund the clinical development of its product cand more_horizontal

OKYO Pharma Ltd (NASDAQ:OKYO) announced that it has completed full enrollment of patients in the randomized portion of the Phase 2 multi-center, doubl more_horizontal

OKYO Pharma Ltd (NASDAQ:OKYO) said it has enrolled 90% of patients in its 240-patient Phase 2 evaluating topical ocular OK-101 to treat dry eye diseas more_horizontal

OKYO Pharma Ltd (NASDAQ:OKYO) has announced it expects to see an increase in the number of patients enrolling on its dry eye disease clinical trial th more_horizontal

OKYO Pharma Ltd (NASDAQ:OKYO) told investors it expects to see considerable enrollments of patients in the ongoing trial of its flagship drug OK-101 t more_horizontal

OKYO Pharma Ltd (LSE:OKYO, NASDAQ:OKYO), an ophthalmology-focused biopharmaceutical company, will showcase two presentations on its dry eye disease (D more_horizontal